Antipodean Advisors’s Atara Biotherapeutics ATRA Stock Holding History

Antipodean Advisors’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$1.48M	Hold	40,000	–	–	7.58%	4
2023 Q2	$1.61M	Hold	40,000	–	–	11.42%	4
2023 Q1	$2.9M	Hold	40,000	–	–	17.94%	3
2022 Q4	$3.28M	Hold	40,000	–	–	10.95%	3
2022 Q3	$3.78M	Hold	40,000	–	–	9.67%	4
2022 Q2	$7.79M	Hold	40,000	–	–	12.69%	4
2022 Q1	$9.29M	Hold	40,000	–	–	6.73%	4
2021 Q4	$15.8M	Sell	40,000 -2,000	-5%	-$842K	6.47%	4
2021 Q3	$18.8M	Buy	42,000 +2,000	+5%	+$717K	5.32%	5
2021 Q2	$15.6M	Hold	40,000	–	–	4.28%	5
2021 Q1	$14.4M	Hold	40,000	–	–	4.44%	5
2020 Q4	$19.6M	Hold	40,000	–	–	5.51%	5
2020 Q3	$13M	Buy	40,000 +8,000	+25%	+$2.72M	4.74%	6
2020 Q2	$11.7M	Buy	32,000 +23,160	+262%	+$5.85M	5.38%	7
2020 Q1	$1.88M	Buy	+8,840	New	+$2.81M	1.74%	7

Other funds holding ATRA

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Antipodean Advisors's ATRA Position: Q3 2023 in Review

Antipodean Advisors held its Atara Biotherapeutics (ATRA) position steady in Q3 2023 at 40,000 shares worth $1.48M. The position accounts for 7.58% of the portfolio, ranked #4.

Antipodean Advisors first reported a position in ATRA in Q1 2020 and has held it in 15 quarters since. The position peaked at $19.6M in Q4 2020. 109 funds tracked by Wall St. Rank hold ATRA as of Q3 2023.

Antipodean Advisors held 40,000 shares of Atara Biotherapeutics worth $1.48M as of Q3 2023.
Antipodean Advisors left its Atara Biotherapeutics share count unchanged in Q3 2023.
Atara Biotherapeutics made up 7.58% of Antipodean Advisors's portfolio in Q3 2023, its #4 holding.
Antipodean Advisors first reported a position in Atara Biotherapeutics in Q1 2020 and has held it in 15 quarters since.
Antipodean Advisors's Atara Biotherapeutics position peaked at $19.6M in Q4 2020.
109 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q3 2023.

Based on Antipodean Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.